In the literature, the verdict is still out whether PTPRU represents an oncogenic or a tumor suppressor gene (Craig and Brady-Kalnay, 2015) but from the limited studies the picture emerges that PCP-2 expression levels are critically determining its scavenger/protector efficacy in the competition with enzymatically active PTP family members for tyrosine phosphorylated substrates, and that its transcript levels are under the tight control of multiple micro-RNAs (Zhou et al., 2016; Dai et al., 2020; Grad et al., 2022). The gene discussed is PTPRU; the disease is neoplasm.